The mainstay therapy for dry eye disease (DED) is the use of artificial tear solutions to supplement the natural tear film1. The therapeutic landscape has recently seen a considerable evolution of topical eye drops. Formulations often incorporate lipid components to address tear lipid deficiency common in meibomian gland dysfunction and the associated evaporative, predominant subtype of DED2. Practitioners seeking guidance in their choice of artificial tear supplements for the treatment of dry eye disease face a dearth of sound scientific evidence. Few studies compare the efficacy of lipid and non-lipid formulations across the breadth of dry eye subtypes and the quality of evidence is generally considered to be poor1-7.
Sign up to keep reading
Create a free Member account at NZ Optics to read this article and more.
- Read all Member articles
- Full digital magazine archive
- Early access to new articles
